Merck & Co. announced this week plans to begin testing a possible cause of Alzheimer’s. The testing is commencing after 200 patients were reviewed for three months while taking MK-8931, an experimental Merck drug which reduces a side effect of the illness. The testing will involve over 3000 patients and with continue for up to 2 years. If successful, the testing may culminate in the first available Alzheimer’s treatment. Read the full article here.